Hjem › Kreft i gallesystemet › Michigan
Kliniske studier for Kreft i gallesystemet i Michigan
9 studier for Kreft i gallesystemet søker deltakere på steder i Michigan.
Byer i Michigan
Offisiell studietekst (engelsk)
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Profound Research -OMG - TriAtria Cancer Center, Farmington Hills
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06760819A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
- Karmanos Cancer Center (Site 109), Detroit
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT07265674A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Research Site, Ann Arbor
- Research Site, Detroit
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07221253Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Grand Rapids
RekruttererFase 2
Alder 18 til 130 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT05489211Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Karmanos Cancer Institiute, Detroit
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT06293898Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Research Site, Grand Rapids
RekruttererFase 3
Alder 18 til 99 · Alle kjønn · Oppdatert 19. aug. 2026 · NCT06467357A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT05592626Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
- Henry Ford Cancer-Detroit, Detroit
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 19. des. 2025 · NCT06065371A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- START Midwest, Grand Rapids
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. des. 2025 · NCT06943521Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.